Bezafibrate improves hypertension and insulin sensitivity in humans.
Bezafibrate improves hypertension and insulin sensitivity in humans.
复制标题
苯扎贝特可改善人类高血压和胰岛素敏感性。
作者：
Jong Il Kim;T. Tsujino;Y. Fujioka;Komei Saito;M. Yokoyama
我们检测了轻度原发性高血压和高脂血症患者的细胞膜脂肪酸组成和胰岛素敏感性，并研究了降脂药物贝扎菲特是否可以通过改善细胞膜脂肪酸组成来改善这些患者的血压升高和胰岛素敏感性。招募了27名受试者。12名患有轻度原发性高血压（收缩压在140 ~ 160 mmHg之间）和高甘油三酯血症（血浆甘油三酯浓度超过150 mg/dl）的男性被指定为HL组。15名患有轻度原发性高血压和正常甘油三酯血症（血浆甘油三酯浓度低于150 mg/dl）的男性被指定为NL组。HL组给予贝扎贝特400mg /dl， NL组给予安慰剂，疗程3个月。Bezafibrate显著降低收缩压（140 +/- 2.6至131.8 +/- 2.6 mmHg，平均+/- SEM）、舒张压（DBP）（87.8 +/- 2.0至82.8 +/- 2.6 mmHg）、空腹血浆甘油三酯浓度（225.5 +/- 23.5至102.9 +/- 10.9 mg/dl）、空腹血浆胰岛素浓度（9.6 +/- 0.8至7.1 +/- 0.8微u /ml）和稳态模型评估评分（HOMA-R, 2.4 +/- 0.2至1.7 +/- 0.2）。HL组胰岛素敏感性指数（56.0 +/- 3.0 ~ 70.7 +/- 4.8 mg × l2/mmol × mU × min）显著提高。在红细胞膜脂肪酸组成方面，贝扎贝特降低了饱和脂肪酸（SFA）的百分比，增加了多不饱和脂肪酸（PUFA）的百分比。在给药前，血浆甘油三酯浓度与HOMA-R （r = 0.50, p < 0.01）、SFA （r = 0.39, p < 0.05）呈正相关，与PUFA （r = -0.45, p < 0.05）呈负相关。综上所述，贝扎贝特对高脂血症的改善可能归因于降低血压和改善胰岛素敏感性。膜脂组成异常可能在这些代谢紊乱中起重要作用。
We examined cellular membrane fatty acid composition and insulin sensitivity in patients with mild essential hypertension and hyperlipidemia, and investigated whether bezafibrate, a lipid-lowering drug, could improve elevated blood pressure and insulin sensitivity in these subjects by ameliorating cellular membrane fatty acid composition. Twenty-seven subjects were recruited. Twelve men with mild essential hypertension [systolic blood pressure (SBP) between 140 mmHg and 160 mmHg] and hypertriglyceridemia (plasma triglyceride concentration over 150 mg/dl) were designated the HL group. Fifteen men with mild essential hypertension and normotriglyceridemia (plasma triglyceride concentration below 150 mg/dl) were designated the NL group. Subjects in the HL group were given bezafibrate 400 mg/dl and those in the NL group were given placebo for 3 months. Bezafibrate significantly reduced SBP (140 +/- 2.6 to 131.8 +/- 2.6 mmHg, mean +/- SEM), diastolic blood pressure (DBP) (87.8 +/- 2.0 to 82.8 +/- 2.6 mmHg), fasting plasma triglyceride concentration (225.5 +/- 23.5 to 102.9 +/- 10.9 mg/dl), fasting plasma insulin concentration (9.6 +/- 0.8 to 7.1 +/- 0.8 microU/ml), and homeostasis model assessment scores (HOMA-R, 2.4 +/- 0.2 to 1.7 +/- 0.2), and significantly improved the insulin sensitivity index (56.0 +/- 3.0 to 70.7 +/- 4.8 mg x l2/mmol x mU x min) in the HL group. Regarding erythrocyte membrane fatty acid composition, bezafibrate reduced the percentages of saturated fatty acids (SFA) and increased the percentage of polyunsaturated fatty acids (PUFA). Plasma triglyceride concentrations were positively correlated with HOMA-R (r = 0.50, p < 0.01) and SFA (r = 0.39, p < 0.05), and negatively correlated with PUFA (r = -0.45, p < 0.05) before administration of placebo or bezafibrate. In conclusion, an improvement of hyperlipidemia by bezafibrate may be attributed to reduction of blood pressure and amelioration of insulin sensitivity. Abnormalities in membrane lipid composition may play an important role in these metabolic disorders.
花生四烯酸的肾 P450 代谢与达尔盐敏感大鼠高血压的发展。
影响因子：
3.2
作者：
Roman,RJ;Alonso-Galicia,M;Wilson,TW
通讯作者：
Wilson,TW
影响因子：
3.2
作者：
Engler, MB;Ma, YH;Engler, MM
通讯作者：
Engler, MM
影响因子：
15.9
作者：
Roden, M;Price, TB;Shulman, GI
通讯作者：
Shulman, GI